The Investment Committee Sample Clauses

The Investment Committee. In order to manage the effective allocation of the LCR SIF in line with the Growth Strategy, a Chief Investment Officer will be appointed to the Executive Management Team. An Investment Committee will be established (reporting to the LCR CA/Mayor) to consider and endorse, return for further work, or reject all business cases, both outline and full, submitted for SIF funding. It is proposed that the Investment Committee will include 3-4 members drawn from the LCRCA and include the relevant Portfolio Lead when decisions are being made relating to their area of work and policy agenda. The Investment Committee will be supported by an Investment Panel which will include a number of key experts procured by the LCRCA to provide specialist advice. The Investment Panel will be responsible for scrutinising the technical review work and project appraisal, which will be carried out by the investment team, led by the Chief Investment Officer. The Panel will then submit a report to the Investment Committee for consideration. The LCR CA/Mayor will make all final project investment decisions, and will in particular, be responsible for approving projects over £3m and ratifying the decisions of the Investment Committee for projects under this threshold.
AutoNDA by SimpleDocs
The Investment Committee. Section 17.1Establishment of Investment Committee. The Company, or its delegate, shall appoint an Investment Committee of at least five Members. The Investment Committee shall control the investment policy of the Plan (subject, in the case of the Company Stock Component, to Sections 11.1 and 17.5 of the Plan) and shall select the Investment Funds under the Plan as described in Section 10.1. If an Investment Committee member who is an employee of the Company ceases to be employed by the Company or an entity that is a member of the Company’s controlled group of corporations, as determined by the Company, or its delegate, then he or she automatically shall be deemed to have resigned from the Investment Committee as of the date of his or her termination of employment. No remuneration shall be paid to any Investment Committee member who is a full time employee of the Company. An Investment Committee member who is not a full time employee of the Company shall be entitled to compensation plus reimbursement of reasonable travel and other expenses.
The Investment Committee. 23 1 Establishment of the Investment Committee..................... 23 2 Appointment of the Investment Committee....................... 24 3 Approval of the Investment Committee.......................... 24
The Investment Committee. 1 Establishment of the Investment Committee The Board of Directors shall establish a loan committee of the Board of Directors (the "Investment Committee") for the purposes hereinafter set forth.

Related to The Investment Committee

  • Investment Committee The board of directors of the insurance company shall appoint an investment committee of the investment manager as the investment committee of the insurance company. The investment committee shall meet at least once each quarter to review the investments and loans of the insurance company.

  • Management Committee The Members shall act collectively through meetings as a "committee of the whole," which is hereby named the "Management Committee." The Management Committee shall conduct its affairs in accordance with the following provisions and the other provisions of this Agreement:

  • Advisory Committee The Settling State shall designate an Opioid Settlement Remediation Advisory Committee (the “Advisory Committee”) to provide input and recommendations regarding remediation spending from that Settling State’s Abatement Accounts Fund. A Settling State may elect to use an existing advisory committee or similar entity (created outside of a State-Subdivision Agreement or Allocation Statute); provided, however, the Advisory Committee or similar entity shall meet the following requirements:

  • Audit Committee (A) The Audit Committee shall be composed of five members who shall be selected by the Board of Directors from its own members, none of whom shall be an officer of the Company, and shall hold office at the pleasure of the Board.

  • Operating Committee the Consortium’s managing body, composed of representatives of the Manager and the Contractors, pursuant to Annex XI.

  • Special Committee The term “Special Committee” shall have the meaning as provided in Section 13(a).

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • INVESTMENT MANAGERS Third party investment managers that manage and direct the investment activities of Investment Funds or are retained to manage and invest a designated portion of the assets of the Master Fund.

  • Executive Committee (A) The Executive Committee shall be composed of not more than nine members who shall be selected by the Board of Directors from its own members and who shall hold office during the pleasure of the Board.

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

Time is Money Join Law Insider Premium to draft better contracts faster.